Anti-VEGF improves visual acuity in eyes with macular edema due to retinal vein occlusion

Hasson, Matt; Pagnani, Michelle; Preston, Courtney
March 2011
Ocular Surgery News;3/25/2011, Vol. 29 Issue 6, p34
Academic Journal
The article reports on the prospective randomized study which reveals that anti-VEGF injection improves visual acruity in eyes with macular edema due to the occlusion of retinal vein.


Related Articles

  • Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome. Beykin, Gala; Grunin, Michelle; Averbukh, Edward; Banin, Eyal; Hemo, Yitzchak; Chowers, Itay // BMC Ophthalmology;2015, Vol. 15 Issue 1, p1 

    Background: To evaluate the long-term outcome of bevacizumab therapy for neovascular age related macular degeneration (NVAMD) in the setting of a clinic. Methods: Consecutive group of NVAMD patients who were treated in a single 3rd referral center with bevacizumab using a loading dosage of 3...

  • Anti-VEGF best option for managing macular edema caused by CRVO. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article offers the insights of doctor Neil M. Bressler regarding the efficacy of monthly intravitreal injection of ranibizumab in treating macular edema caused by central retinal vein occlusion (CRVO).

  • New kid on the block. Krader, Cheryl Guttman; Korobelnik, Jean-Francois // Ophthalmology Times;3/1/2013, Vol. 38 Issue 5, p26 

    The article reports on a randomized, sham-controlled GALILEO study that was conducted in Europe and Asia to determine efficacy of anti-vascular endothelial growth factors (VEGF) agent in treating patients with CRVO-related macular edema. It mentions that the study involved patients with mean age...

  • Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture. Klettner, Alexa; Recber, Muhammed; Roider, Johann // Graefe's Archive of Clinical & Experimental Ophthalmology;Oct2014, Vol. 252 Issue 10, p1593 

    Purpose: Anti-VEGF treatment is the therapy of choice in age-related macular degeneration and is also applied in diabetic macular edema or retinal vein occlusion. Recently, aflibercept has been approved for therapeutic use. In this study, we investigate the efficacy of aflibercept in comparison...

  • NEWTON: Aflibercept injection for previously treated macular edema associated with central retinal vein occlusions. Khuran, Rahul; Olsen, Timothy W. // Ocular Surgery News;7/25/2013, Vol. 31 Issue 14, p27 

    The article focuses on a study which investigated the therapeutic use of intravitreal aflibercept injection for treatment of macular edema following central retinal vein occlusion. It details the methodology of the study authored ophthalmologists from Northern California Retina Vitreous...

  • Submacular hemorrhages may be managed with anti-VEGF. Biro, Ashley; Nale, Patricia // Ocular Surgery News;2/25/2013, Vol. 31 Issue 4, p36 

    The article discusses the management of thin to moderate submacular hemorrhages, which can be taken care of through anti-vascular endothelial growth factor (VEGF) therapy.

  • Full thickness macular hole case after intravitreal aflibercept treatment. Yuji Oshima; Apte, Rajendra S.; Shintaro Nakao; Shigeo Yoshida; Tatsuro Ishibashi // BMC Ophthalmology;2015, Vol. 15 Issue 1, p1 

    Background: The pathogenesis of macular hole formation is widely accepted as a tractional force at the vitreo-retinal interface in fovea. We report a case of macular hole after intravitreous aflibercept injection for age-related macular degeneration (AMD) associated with contraction of the...

  • HIGHER-AFFINITY AGENTS: AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Heier, Jeffrey S. // Johns Hopkins Advanced Studies in Ophthalmology;Feb2013, Vol. 10 Issue 1, p43 

    The article presents two studies results based on information collected at different stages of 52 weeks and 96 weeks showing the change in pattern for treatment of the anti-vascular endothelial growth factor (VEGF). It states that the agents were used to treat patients with neo-vascular (wet)...

  • Judicious use of anti-VEGF agents advised as 'reasonable'. Reichel, Elias // Ocular Surgery News;3/10/2011, Vol. 29 Issue 5, p18 

    The article reports on the reasonable advice on the judicious use of anti-vascular endothelial growth factors (VEGF) agents for age-related macular degeneration (AMD) treatment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics